- Conditions
- Pandemic Influenza Immunization, Healthy Volunteers
- Interventions
- Pandemic flu H5 HA mRNA SD2 vaccine, Placebo
- Biological · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 720 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 13
- States / cities
- La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2425–2448
of 10,572
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD
- Interventions
- Itolizumab, EQ001 Placebo
- Biological · Drug
- Lead sponsor
- Equillium
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 31 more
- Conditions
- Dermatitis Atopic
- Interventions
- Blood sample, Cheek swab
- Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 0 Years to 11 Years
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Los Angeles, California + 16 more
- Conditions
- Myasthenia Gravis
- Interventions
- Rituximab, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Davis, California • Los Angeles, California + 22 more
- Conditions
- Emphysema
- Interventions
- Spiration Valve System, Medical Management
- Device · Other
- Lead sponsor
- Olympus Corporation of the Americas
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 32
- States / cities
- Fort Smith, Arkansas • Riverside, California • San Diego, California + 28 more
- Conditions
- Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
- Interventions
- Enzalutamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 95
- States / cities
- Colorado Springs, Colorado • Lakewood, Colorado • Lone Tree, Colorado + 57 more
- Conditions
- Opioid Use, Stimulant Use
- Interventions
- harm reduction intervention
- Behavioral
- Lead sponsor
- Brittany Miller-Roenigk
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Cincinnati, Ohio
- Conditions
- Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 493
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more
- Conditions
- Depression, Pain
- Interventions
- Duloxetine Hydrochloride
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 25
- States / cities
- Peoria, Arizona • Burbank, California • Fresno, California + 22 more
- Conditions
- HSV Infection
- Interventions
- Pritelivir, ESO and pritelivir
- Drug
- Lead sponsor
- AiCuris Anti-infective Cures AG
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Psoriasis
- Interventions
- MEDI-522, Placebo
- Drug · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Fresno, California • Vallejo, California + 15 more
- Conditions
- Anemia, Chronic Kidney Disease
- Interventions
- AKB-6548, Placebo
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years to 82 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 47
- States / cities
- Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more
- Conditions
- Ischemic Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Juventas Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Gainsville, Florida • Tampa, Florida + 11 more
- Conditions
- Venous Thromboembolism (VTE)
- Interventions
- Betrixaban, Enoxaparin
- Drug
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 7,513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Amprenavir, Efavirenz, Saquinavir, Lamivudine, Stavudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2002
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 23 more
- Conditions
- Contraception
- Interventions
- ESS505 (BAY1454033)
- Device
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 21 Years to 44 Years · Female only
- Enrollment
- 660 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2024
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • Denver, Colorado • Wellington, Florida + 14 more
- Conditions
- Migraine, With or Without Aura
- Interventions
- Rimegepant, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tempe, Arizona + 45 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 42
- States / cities
- Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
- Conditions
- Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7
- Interventions
- Bevacizumab, Capecitabine, Carboplatin, Laboratory Biomarker Analysis, Oxaliplatin, Paclitaxel, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 248
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 163 more
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
- Interventions
- Dexamethasone Early, Dexamethasone Late
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 13 Days to 15 Days
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 1994
- U.S. locations
- 13
- States / cities
- Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
- Conditions
- Migraine Disorders
- Interventions
- NP101
- Drug
- Lead sponsor
- NuPathe Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 28 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Darapladib 160 mg, Placebo, Standard Therapy
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13,026 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 290
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more
- Conditions
- COVID-19
- Interventions
- NVX-CoV2373 (5μg), NVX-CoV2601(5μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 994 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Banning, California + 44 more
- Conditions
- HIV Infections
- Interventions
- Lopinavir/ritonavir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 28
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 21 more